This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, as well as discusses the interleukin(IL)-17 class of biologics, how this class compares to other classes such as IL-23 and TNFα, and how bimekizumab sets itself apart from other biologics in the pipeline for psoriasis.
The podcast The Cutaneous Connection is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.